Zila Transitions to Cancer Detection Company
November 29 2006 - 8:30AM
Business Wire
Zila, Inc. (NASDAQ GM: ZILA), has completed the acquisition of
Professional Dental Technologies, Inc. (�Pro-Dentec��) a
privately-held, profitable dental products company headquartered in
Arkansas, in a $34 million cash transaction. Pro-Dentec generates
annual revenue of approximately $35 million and EBITDA of
approximately $5 million. �With the acquisition of Pro-Dentec, we
have completed a remarkable transformation of Zila into a cancer
detection company. Pro-Dentec provides us the means to distribute
our oral cancer detection products directly to dental professionals
through a highly-regarded national sales force that is already
profitably selling complementary Soft Tissue Management (STM�)
products; oral cancer is a life threatening soft tissue disease.
Pro-Dentec�s national sales, marketing and distribution capability
provides the infrastructure required to establish our oral cancer
detection products as the standard of care in dental offices
nationally,� stated Douglas D. Burkett, Ph.D., Chairman, Chief
Executive Officer and President of Zila, Inc. Pro-Dentec conducts
approximately 115 continuing education seminars for dentists and
their staffs each year that are certified by the American Dental
Association and the Academy of General Dentistry. These seminars
are ideally suited to train a large number of dental professionals
on the importance of oral cancer screening. Zila believes that its
new national sales and marketing force will enable the rapid growth
of ViziLite Plus and, following FDA approval, OraTest. �According
to the American Cancer Society, the incidence of oral cancer has
grown while other major cancers have decreased. Pro-Dentec has the
capability to reach most of the nation�s dentists and has
well-established, ongoing relationships with a large number of
dental offices. The screening of at-risk patients with ViziLite
Plus at dental offices within Pro-Dentec�s existing customer base
will provide enormous growth for Zila while saving lives,� stated
Dr. Frank Bellizzi, President of Zila Pharmaceuticals, Inc. To
facilitate the acquisition of Pro-Dentec, the Company completed two
tranches of a $40 million Private Placement of equity and debt
through its financial advisor and placement agent, Roth Capital
Partners, with the final $16 million tranche for future working
capital scheduled to fund today. About Zila, Inc. Zila, Inc.,
headquartered in Phoenix, is a leading cancer diagnostic company
initially focused on oral cancer: Zila Pharmaceuticals is dedicated
to establishing ViziLite� Plus as the new standard of care for the
early detection of oral abnormalities that could lead to cancer,
with initial focus on the dental market through Pro-Dentec�, a
leading designer, manufacturer and marketer of products exclusively
to dental professionals for Soft Tissue Management (STM�) including
the Rota-dent� Professional Powered Brush, the Pro-Select3�
Piezo-Ultrasonic Scaler System and a suite of pharmaceutical STM�
products for both in-office and home-care use. Zila Biotechnology
is focused on achieving regulatory approval for the next generation
oral cancer diagnostic, OraTest�, followed by the development of
additional applications of its cancer detection technologies. For
more information about Zila, visit www.zila.com. This press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. These forward-looking statements are based
largely on Zila's expectations or forecasts of future events, can
be affected by inaccurate assumptions and are subject to various
business risks and known and unknown uncertainties, a number of
which are beyond the Company's control. Therefore, actual results
could differ materially from the forward-looking statements
contained herein. A wide variety of factors could cause or
contribute to such differences and could adversely impact revenues,
profitability, cash flows and capital needs. There can be no
assurance that the forward-looking statements contained in this
press release will, in fact, transpire or prove to be accurate. For
a more detailed description of these and other cautionary factors
that may affect Zila's future results, please refer to Zila's Form
10-K for its fiscal year ended July 31, 2006. Zila, Inc. (NASDAQ
GM: ZILA), has completed the acquisition of Professional Dental
Technologies, Inc. ("Pro-Dentec(R)") a privately-held, profitable
dental products company headquartered in Arkansas, in a $34 million
cash transaction. Pro-Dentec generates annual revenue of
approximately $35 million and EBITDA of approximately $5 million.
"With the acquisition of Pro-Dentec, we have completed a remarkable
transformation of Zila into a cancer detection company. Pro-Dentec
provides us the means to distribute our oral cancer detection
products directly to dental professionals through a highly-regarded
national sales force that is already profitably selling
complementary Soft Tissue Management (STM(R)) products; oral cancer
is a life threatening soft tissue disease. Pro-Dentec's national
sales, marketing and distribution capability provides the
infrastructure required to establish our oral cancer detection
products as the standard of care in dental offices nationally,"
stated Douglas D. Burkett, Ph.D., Chairman, Chief Executive Officer
and President of Zila, Inc. Pro-Dentec conducts approximately 115
continuing education seminars for dentists and their staffs each
year that are certified by the American Dental Association and the
Academy of General Dentistry. These seminars are ideally suited to
train a large number of dental professionals on the importance of
oral cancer screening. Zila believes that its new national sales
and marketing force will enable the rapid growth of ViziLite Plus
and, following FDA approval, OraTest. "According to the American
Cancer Society, the incidence of oral cancer has grown while other
major cancers have decreased. Pro-Dentec has the capability to
reach most of the nation's dentists and has well-established,
ongoing relationships with a large number of dental offices. The
screening of at-risk patients with ViziLite Plus at dental offices
within Pro-Dentec's existing customer base will provide enormous
growth for Zila while saving lives," stated Dr. Frank Bellizzi,
President of Zila Pharmaceuticals, Inc. To facilitate the
acquisition of Pro-Dentec, the Company completed two tranches of a
$40 million Private Placement of equity and debt through its
financial advisor and placement agent, Roth Capital Partners, with
the final $16 million tranche for future working capital scheduled
to fund today. About Zila, Inc. Zila, Inc., headquartered in
Phoenix, is a leading cancer diagnostic company initially focused
on oral cancer: -- Zila Pharmaceuticals is dedicated to
establishing ViziLite(R) Plus as the new standard of care for the
early detection of oral abnormalities that could lead to cancer,
with initial focus on the dental market through Pro-Dentec(R), a
leading designer, manufacturer and marketer of products exclusively
to dental professionals for Soft Tissue Management (STM(R))
including the Rota-dent(R) Professional Powered Brush, the
Pro-Select3(R) Piezo-Ultrasonic Scaler System and a suite of
pharmaceutical STM(R) products for both in-office and home-care
use. -- Zila Biotechnology is focused on achieving regulatory
approval for the next generation oral cancer diagnostic,
OraTest(R), followed by the development of additional applications
of its cancer detection technologies. For more information about
Zila, visit www.zila.com. This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. These forward-looking statements are based largely on
Zila's expectations or forecasts of future events, can be affected
by inaccurate assumptions and are subject to various business risks
and known and unknown uncertainties, a number of which are beyond
the Company's control. Therefore, actual results could differ
materially from the forward-looking statements contained herein. A
wide variety of factors could cause or contribute to such
differences and could adversely impact revenues, profitability,
cash flows and capital needs. There can be no assurance that the
forward-looking statements contained in this press release will, in
fact, transpire or prove to be accurate. For a more detailed
description of these and other cautionary factors that may affect
Zila's future results, please refer to Zila's Form 10-K for its
fiscal year ended July 31, 2006.
Zila (NASDAQ:ZILA)
Historical Stock Chart
From May 2024 to Jun 2024
Zila (NASDAQ:ZILA)
Historical Stock Chart
From Jun 2023 to Jun 2024